Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by GoTogetheron Nov 11, 2017 4:06pm

154 Views

Post# 26945847

After the last NR, this Video Explains a lot

- "... NMIBC originating in the upper ureter is due to Lynch's Syndrome."
Around 18.30 minutes

Also very interesting to note :
- "...The bladder is a reservoir for toxins ..."
- "...There's probably not one gene responsible for Bladder Cancer ..."
- "...The idea that one pill is going to target one gene, and fix Bladder Cancer, I think that's a very long shot ..." ( Here's where Theralase doesn't fit in. It's not a pill manufacturer. Theralase's approach is very different > disruptive technology )
Around 25.30 minutes

Many thanks who put this Video (presented by Professor Terence Friedlander) here first.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?